Loading
The anti-stroma antibody pamrevlumab did not help people with locally advanced pancreatic cancer live longer.
LAPIS randomised patients with locally advanced, unresectable pancreatic ductal adenocarcinoma to pamrevlumab or placebo with either gemcitabine plus nab-paclitaxel or FOLFIRINOX, with the aim of increasing resection and survival. FibroGen reported in 2024 that the trial did not meet its primary overall survival endpoint.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Pamrevlumab + chemotherapy (gemcitabine-nab-paclitaxel or FOLFIRINOX) | 143 | 17.25 months | 1.08 (0.83 to 1.41) | 0.5487 | link |
| Placebo + chemotherapy | 141 | 17.94 months | ||||
| Progression-free survival (RECIST 1.1) | Pamrevlumab + chemotherapy | 143 | 9.36 months | - | - | link |
| Placebo + chemotherapy | 141 | 9.4 months |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares FibroGen, Pamrevlumab, FOLFIRINOX / mFOLFIRINOX, Metastatic pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, FOLFIRINOX / mFOLFIRINOX, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/